AstraZeneca says its blockbuster Farxiga proved to be a game-changer in CKD — wrapping PhIII early

John Carroll

Editor & Founder

If the FDA can still hold up its end of the bargain, AstraZeneca is already on a short path to scooping up a cutting-edge win with a likely approval for their SGLT2 drug Farxiga in cutting the risk of heart failure. Now the pharma giant says it can point to solid evidence that the drug — initially restricted to diabetes — also works for chronic kidney disease, potentially adding a blockbuster indication for the franchise.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

AstraZeneca says its blockbuster Farxiga proved to be a game-changer in CKD — wrapping PhIII early

John Carroll

Editor & Founder

To read Endpoints News become a free subscriber

AstraZeneca enlists UK Treg biotech for type 1 diabetes, inflammatory bowel disease deal featuring $85M upfront

Who pays the most (and least) in biopharma? We crunched median salary data from 175 companies

FDA sets December approval decision for first CRISPR therapy, with 94% of patients free of sickle cell crises

Editas gives first look at CRISPR data in sickle cell, beta thalassemia six months after layoffs, refocus

Lyndra Therapeutics eyes $180M Series D for potential 2026 launch of once-weekly schizophrenia med

The new rules of cancer care: Responding to increasing CMS influence on the oncology landscape

As­traZeneca says its block­buster Farx­i­ga proved to be a game-chang­er in CKD — wrap­ping PhI­II ear­ly

John Carroll

Editor & Founder

To read Endpoints News become a free subscriber

As­traZeneca en­lists UK Treg biotech for type 1 di­a­betes, in­flam­ma­to­ry bow­el dis­ease deal fea­tur­ing $85M up­front

Who pays the most (and least) in bio­phar­ma? We crunched me­di­an salary da­ta from 175 com­pa­nies

FDA sets De­cem­ber ap­proval de­ci­sion for first CRISPR ther­a­py, with 94% of pa­tients free of sick­le cell crises

Ed­i­tas gives first look at CRISPR da­ta in sick­le cell, be­ta tha­lassemia six months af­ter lay­offs, re­fo­cus

Lyn­dra Ther­a­peu­tics eyes $180M Se­ries D for po­ten­tial 2026 launch of once-week­ly schiz­o­phre­nia med

The new rules of can­cer care: Re­spond­ing to in­creas­ing CMS in­flu­ence on the on­col­o­gy land­scape

AstraZeneca says its blockbuster Farxiga proved to be a game-changer in CKD — wrapping PhIII early

AstraZeneca enlists UK Treg biotech for type 1 diabetes, inflammatory bowel disease deal featuring $85M upfront

Who pays the most (and least) in biopharma? We crunched median salary data from 175 companies

FDA sets December approval decision for first CRISPR therapy, with 94% of patients free of sickle cell crises

Editas gives first look at CRISPR data in sickle cell, beta thalassemia six months after layoffs, refocus

Lyndra Therapeutics eyes $180M Series D for potential 2026 launch of once-weekly schizophrenia med

The new rules of cancer care: Responding to increasing CMS influence on the oncology landscape